FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett Company Inc.
18/06/2026 18:01
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett Company Inc. June 18 (Reuters) - The U.S. Federal Trade Commission is requiring Aurobindo Pharma Limited ARBN.NS to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc., the agency said on Thursday in a statement.
(Reporting by Ryan Patrick Jones, Writing by Christian Martinez; Editing by Doina Chiacu)
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma USA Receives FTC Approval To Acquire Lannett Company
Brief: Aurobindo Pharma Obtains US FTC Approval For Lannett Acquisition
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett (updated)
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett Company Inc.
HSBC sees no earnings hit from FDA action on India's Aurobindo Pharma